Pfizer Manufacturing Belgium BV

Primary objectives: Phase Ib: Determine the safety profile of Elranatamab in Chinese subjects to confirm RP2D Phase II: Determine the efficacy of Elranatamab in Chinese RRMM subjects Secondary objectives: 1. Further evaluate the efficacy of Elranatamab in Chinese RRMM subjects 2. Determine the safety and tolerability of Elranatamab 3. Evaluate the PK of Elranatamab 4. Evaluate the immunogenicity of Elranatamab 5. Evaluate the effect of Elranatamab on patient-reported symptoms and function Exploratory objectives: 1. Explore the association between Elranatamab exposure and biomarkers, safety, and PD/biomarker endpoints 2. Explore the relationship between Elranatamab and MM biology in subjects

Primary objective: To evaluate the pharmacokinetic characteristics of Vupanorsen 80 mg and 160 mg after single subcutaneous injection in healthy Chinese adults Secondary objective: To evaluate the safety and tolerability of Vupanorsen 80 mg and 160 mg after single subcutaneous injection in healthy Chinese adults. To evaluate the pharmacodynamics of Vupanorsen 80 mg and 160 mg after single subcutaneous injection in healthy Chinese adults.

Primary Objectives: Phase Ib: Evaluate the incidence of DLTs for PF-06801591 Phase II: Compare PF-06801591 exposure of 600 mg SC Q6W vs. 300 mg SC Q4W based on area under the concentration-time curve (AUCτ) within the dosing interval (τ) and steady-state Ctrough Secondary Objectives: Evaluate overall safety and tolerability Describe PK profile (Phase Ib and Phase II) Describe immunogenicity Evaluate antitumor activity Evaluate the correlation between clinical efficacy and PD-L1 expression in baseline tumor tissue